Clinical trial

Randomized, Open-label, Adaptive, Controlled, Phase III Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of Reimmunization With Third Dose of Homologous vs. Heterologous Vaccine Against COVID-19 in Patients Undergoing Solid Organ Transplantation: Liver, Heart, Kidney and Lung.

Name
REIN-TX
Description
Patients undergoing solid organ transplantation randomly selected from those who have received two doses of Spikevax (Moderna) vaccine, provided that a minimum of 8 weeks have elapsed from the second dose to the time of the start of the trial. It is planned to include 386 patients.
Trial arms
Trial start
2021-09-01
Estimated PCD
2021-09-01
Trial end
2021-09-01
Status
Withdrawn
Phase
Early phase I
Treatment
Janssen vaccine
0.5 ml millilitre(s) Intramuscular use
Arms:
HETEROLOGOUS VACCINE
Other names:
Janssen Biologics B.V., EU/1/20/1525/001 EU/1/20/1525/002
Spikevax (Moderna) vaccine
0.5 ml millilitre(s) Intramuscular use
Arms:
HOMOLOGOUS VACCINE
Other names:
MODERNA BIOTECH SPAIN, S.L., EU/1/20/1507/001
Primary endpoint
Changes in the production of anti-S1-RBD IgG antibodies.
28 days
Eligibility criteria
Inclusion Criteria: 1. Patients who underwent solid organ transplantation prior to revaccination against COVID-19. 2. Patients who have received the full COVID-19 vaccination regimen with Spikevax (Moderna) vaccine, with a minimum of 8 weeks having elapsed from the second dose to the time of trial initiation. 3. Age \> 18 years. 4. All participants must have previously agreed to participate in the study by signing the informed consent form. Exclusion Criteria: 1. Having suffered SARS-CoV-2 infection at any time prior to inclusion in the study. 2. Subjects without solid organ transplantation or with a different solid organ (e.g. pancreas transplantation) and without any type of immunosuppression (immunocompetent non-transplanted) from the general population. 3. Age \< 18 years 4. Temperature of at least 38°C in the 24 hours prior to immunization or other clinically relevant acute symptomatology. 5. Clinical manifestations compatible with COVID-19 infection at the time of evaccination. 6. Known allergy or history of anaphylaxis or other serious adverse events to the administration of vaccines or their excipients. 7. Any other condition that contraindicates vaccination against SARSCov2, including pregnancy. 8. Having presented graft rejection in the 15 days prior to the start of the study. 9. Any condition or situation that may interfere with the ability to maintain adherence to study procedures and visits.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 0, 'type': 'ACTUAL'}}
Updated at
2023-03-02

1 organization

2 products

1 indication

Product
Janssen
Indication
COVID-19
Product
Spikevax